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ABSTRACT: 
 
Objective: The objective of this surveillance project was to determine the prevalence of 
mixed connective tissue disease (MCTD) in 2007 in the Indian Health Service (IHS) 
active clinical population from 3 regions of the United States. 
Methods: The IHS Lupus Registry was designed to identify possible MCTD cases in 
addition to lupus.  The population denominator for this report includes American Indian 
or Alaska Native adults within the IHS active clinical population in 2007, residing in 
select communities in 3 regions of the US.  Potential MCTD cases were identified using 
a broad range of diagnostic codes and were confirmed by detailed medical record 
abstraction.  Classification as MCTD for this analysis required both rheumatologist 
diagnosis of MCTD without diagnosis of other connective tissue disease and 
documentation of the Alarcón-Segovia criteria in the medical record.  Prevalence was 
also calculated using two alternate definitions of MCTD.   
Results:  The age-adjusted prevalence of MCTD using our primary definition was 6.4 
per 100,000 (95% confidence interval (CI) 2.8-12.8).  The prevalence was higher in 
women than men using all three definitions of MCTD, and no men met the primary 
definition of MCTD.   
Conclusion: The first population-based estimates of the prevalence of MCTD in the US 
American Indian/Alaska Native population show that the prevalence appears to be 
higher than in other populations.  Additional population-based estimates are needed to 
better understand the epidemiology of MCTD. 
 
Abstract word count: 225 
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Significance and Innovation: 
• This study provides the first description of MCTD prevalence in American Indian 
and Alaska Native populations. 
• Data from this study suggest that the prevalence of MCTD in US American 
Indian/Alaska Native populations may be higher than other populations studied, 
though the confidence intervals are wide. 
• Additional studies of MCTD epidemiology in minority populations are needed.  
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Mixed connective tissue disease (MCTD) was first described in 1972 as a condition 
encompassing a set of overlapping features of connective tissue disease in patients 
with antibodies to ribonucleoprotein (RNP).1  Since the initial description, there has 
been some debate as to whether this represents a distinct clinical entity, versus an early 
presentation that evolves over time into a specific connective tissue disease.2,3  
However, several studies have found that evolution of MCTD into other connective 
tissue diseases occurs infrequently.4,5  Four sets of classification criteria have been 
developed for MCTD, most of which include a requirement for positive serology (anti-
RNP) and at least three clinical features.6    The Alarcón-Segovia criteria require 
positive serology and at least three of the following clinical features (of which one must 
be either synovitis or myositis): edema of hands, synovitis, myositis, Raynaud’s 
phenomenon, and acrosclerosis.7 
 
Few studies have investigated the prevalence or incidence of MCTD in populations.  In 
Norway,8 a nationwide study found the point prevalence of living adult MCTD in 2008 to 
be 3.8 per 100,000 (95% CI 3.2-4.4), with a female predominance.  In this study, the 
incidence of adult-onset MCTD from 1996 to 2005 was 2.1 per million per year.  A 
recent study in the United States described an annual incidence of MCTD of 1.9 per 
100,000 from 1985-2014.5 The incidence of MCTD in Finland was found to be 8.4 per 
million in 1990.9  Other studies have followed cohorts of patients with MCTD and 
described the clinical features but have not focused on the epidemiology of the disease 
in adults.4,10,11  
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Disparities in the epidemiology of autoimmune diseases across populations can lead to 
insight into the pathogenesis of disease.  We recently reported a high prevalence and 
incidence of SLE in a population-based registry of American Indian/Alaska Native 
(AI/AN) people receiving care through Indian Health Service (IHS) or tribal health 
facilities.12    Because of the clinical impression of rheumatologists in the IHS that MCTD 
might be more common in this population than in others, as well as previous data 
suggesting that “overlap syndromes” may be common in indigenous North American 
populations,13 we designed the registry from the outset to capture suspected cases of 
MCTD in addition to SLE.  If MCTD were more common in the AI/AN population than 
SLE, this might lead to improved understanding of its etiology as well as guide the 
rheumatologic care for this population.  The objective of this project was to determine 
the prevalence of MCTD in 2007 in the IHS Lupus Registry. 
 
PATIENTS AND METHODS:  
The IHS Lupus Registry was created in 2011 with the primary objective to 
retrospectively determine the prevalence of SLE in 2007 and incidence of SLE from 
2007-2009 in the AI/AN population.  The registry was also designed to determine the 
prevalence of MCTD in 2007 by capturing MCTD classification elements.  The 
population denominator includes adults age 18 and older living within the IHS Lupus 
Registry target areas in 2007, including select communities as previously described12 in 
the Alaska, Phoenix, and Oklahoma City IHS Areas.  Communities selected for 
inclusion in the registry were those where access to rheumatology specialist 
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consultation was available within the IHS system (direct care) at the time of 
development of the registry.   
 
Potential cases of SLE or MCTD were ascertained from the IHS National Data 
Warehouse using the following International Classification of Diseases, 9th Revision 
(ICD-9) codes: 710.0, 710.8, 710.9, 695.4, 710.1, and 710.4.  We included these codes 
for SLE, undifferentiated connective tissue disease, discoid lupus, systemic sclerosis, 
and polymyositis to capture a broader range of patients who may ultimately be 
diagnosed with SLE or MCTD.  MCTD does not have its own ICD-9 code, but is typically 
coded as 710.8 (other specified diffuse diseases of connective tissue).  For each 
potential case, field medical record abstraction was performed at each clinic or hospital 
in the 3 regions as described previously.12  Specifically, medical records from each 
facility were reviewed from the earliest available archived paper record through the end 
of 2009.   In addition to abstracting data elements relevant to both SLE and MCTD 
(including anti-RNP, synovitis, myositis, and Raynaud’s phenomenon, all of which are 
included in the Alarcón-Segovia MCTD classification criteria), we abstracted the 
remaining Alarcón-Segovia clinical criteria for MCTD (edema of the hands and 
acrosclerosis or sclerodactyly).7  Due to the limitations of medical record review with 
multiple laboratories used for anti-RNP testing, we did not require high-titer anti-RNP, 
differing from the Alarcon-Segovia requirement of hemagluttinin titer >=1:1600.  We did 
exclude anti-RNP if it was marked as “equivocal/borderline” by the local laboratory.  The 
treating physician’s final diagnosis and the specialty of the physician making the 
diagnosis were also recorded.   
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 Our primary case definition was the treating rheumatologist’s diagnosis of MCTD 
without other rheumatologist-diagnosed connective tissue disease and with 
documentation in the medical record that the Alarcón-Segovia criteria were met.  This 
was selected in order to best compare our results to the Norwegian population-based 
study of MCTD, as described above.8    The rationale for using the Alarcón-Segovia 
criteria rather than other MCTD criteria was that the data elements required were more 
readily captured by our methods (abstraction of existing medical records, with focus on 
SLE-related data elements) than the other 3 sets of criteria.6  Two secondary case 
definitions were used: 1) meeting the Alarcón-Segovia criteria for MCTD (criteria 
definition); and 2) the treating rheumatologist’s diagnosis of MCTD without other 
rheumatologist-diagnosed connective tissue disease (rheumatologist-diagnosed 
definition).  The first alternate definition (criteria definition) was selected for its similarity 
to the methods used in our analysis of the prevalence of SLE in the IHS Lupus Registry.  
The second alternate definition was selected to represent the burden of MCTD in a real 
world clinical care setting.  There were no specific exclusions based on classification 
criteria for other diseases. 
   
Prevalence of MCTD was calculated using the number of cases meeting the primary or 
alternate definitions with a date of diagnosis of 2007 or earlier divided by the number of 
adults in the 2007 denominator, expressed as a rate per 100,000.  All individuals in the 
numerator and denominator were alive as of January 1, 2007.  Prevalence was 
calculated overall, by sex, and by age.  Age-adjusted rates were calculated overall 
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using the 2000 projected US population.14  Male and female rates were not age-
adjusted due to the small number of cases.  95% confidence intervals (CIs) were 
calculated around each proportion.  Statistical analyses were performed using SAS 
version 9.3 (SAS Institute, Cary NC), and STATA (STATA/IC version 11.2 for Windows, 
StataCorp LP, College Station, TX). 
 
The project was reviewed by the Institutional Review Boards (IRBs) of the participating 
regions and determined to be a public health activity (not research). Tribal approval was 
obtained from participating tribal health organizations. 
 
RESULTS:  
The prevalence of MCTD in AI/AN adults in our registry is shown in Table 1.  Because 
of the small number of cases in men, the total number of cases is presented overall but 
not by gender.  By the primary definition, the age-adjusted prevalence was 6.4 per 
100,000 (95% CI: 2.8-12.8).  The unadjusted prevalence in women was 10.7 per 
100,000, with no cases found in men using the primary definition. By the criteria 
definition, the age-adjusted prevalence was higher at 26.3 per 100,000 (95% CI: 17.4-
38.0).  Using the rheumatologist-diagnosed definition, the age-adjusted prevalence was 
intermediate at 19.4 per 100,000 (95% CI: 12.2-29.3), not statistically significantly 
different from the criteria definition.  Using the rheumatologist-diagnosed definition, the 
female to male ratio was the highest at 16:1.  Using the primary definition and restricting 
to those with adult-onset MCTD (similar to the analysis from Norway8) gives a 
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prevalence of 5.5 per 100,000 (95% CI: 2.7-11.3) and age-adjusted prevalence of 5.7 
(95% CI: 2.3-11.9) (data not shown). 
 
Point estimates of age-specific prevalence by case definition are shown in Figure 1.  
Although our small numbers preclude statements of statistical significance, the primary 
definition had lower rates than the alternate definitions in all age groups, with the 
highest rates in ages 45-64 and no cases age 65 or over.   The small number of cases 
precludes accurate description of the most common age at onset of MCTD, though the 
majority of cases (80-95%) had onset between the ages of 21-60.  For cases meeting 
our primary case definition of MCTD in 2007, the median year of onset was 1999. 
 
Table 2 shows the frequency of individual Alarcón-Segovia criteria documented in the 
medical record among prevalent cases by each definition of MCTD.  Of note, 100% of 
patients meeting the primary or criteria definition had the presence of anti-RNP 
antibodies documented in the medical record, while only 60.9% of those meeting the 
rheumatologist-diagnosed definition had evidence of positive anti-RNP in the medical 
record.  Of 9 individuals without a documented positive anti-RNP, 4 had a negative 
result in the medical record at some time, while 5 had missing data.  Those meeting the 
rheumatologist-diagnosis definition had a lower prevalence of all clinical criteria as well.  
The most common clinical criteria met for all definitions were Raynaud’s phenomenon 
and synovitis, while the least common criteria met for all definitions were myositis and 
acrosclerosis.  Of the 22 cases meeting the criteria definition but not diagnosed with 
MCTD by a rheumatologist, 10 of those never had a documented consultation with a 
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rheumatologist, 7 were diagnosed with both MCTD and SLE by a rheumatologist, and 
the remaining 5 had diagnoses of other connective tissue disorders.   
 
DISCUSSION:   
In the IHS Lupus Registry, the age-adjusted prevalence of MCTD by our primary 
definition was 6.4 per 100,000 adults.   The range from lowest to highest prevalence 
was from 6.4 (primary definition) to 26.3 per 100,000 (criteria definition).  By all 
definitions, MCTD was more common in women, with the lowest female:male ratio of 
6:1.   
 
There is limited information about the prevalence of MCTD in populations.  A recent 
study in the US described the incidence of MCTD.5  Our project is the second to report 
on incidence or prevalence in any US population and the first to report on the AI/AN 
population specifically.    The prevalence of MCTD by our primary case definition was 
higher than that found in previous studies and we suspect that given our higher point 
estimate, the prevalence of MCTD is truly higher in the AI/AN population than in 
Norway.  However, given the small number of cases and wide confidence intervals in 
this study, we cannot determine whether this difference is due to chance.  The age-
adjusted prevalence using our primary definition was 6.4 per 100,000 (95% CI: 2.8-
12.8), while the prevalence in Norway was 3.8 per 100,000 (95% CI: 3.2-4.4).8  
Although the prevalence of MCTD may be higher in the AI/AN population than in other 
US populations, no other US data on prevalence are available for comparison.  A recent 
publication reported the incidence of MCTD in Olmsted County, Minnesota to be 1.9 per 
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100,000,5 higher than studies of incidence in other countries.  Based on this information, 
it is possible that the prevalence of MCTD in AI/AN populations is no higher than other 
US populations.  It is important to note that although MCTD appears to be more 
common in AI/AN populations, as in other populations studied it remains less common 
than SLE.  In our registry, we found the age-adjusted prevalence of SLE in 2007 to be 
178 per 100,000,12 approximately 7 times more prevalent than MCTD. 
 
Our second alternate definition was a rheumatologist’s diagnosis of MCTD without any 
other rheumatologist-diagnosed connective tissue disease.  Unlike the other definitions, 
not all individuals in this category had documented anti-RNP positivity.  In addition, a 
smaller proportion met each of the individual clinical criteria.  It is possible that this 
definition overestimates the prevalence of MCTD and that some of these individuals 
would be better categorized as having undifferentiated connective tissue disease.  For 
this reason we did not consider rheumatologist-diagnosed MCTD as our primary 
definition, but we   included this definition because we felt that this may be a better 
representation of real world burden of diagnosed disease.   
 
This project has some limitations in addition to those related to rheumatologist-
diagnosed MCTD.  First, data collection was limited to the existing medical record.  
Some criteria for MCTD might have been met but not documented in the medical 
record, and we were not able to examine, interview, or collect serum from patients to 
validate the criteria.  For example, in cases identified by rheumatologists as MCTD for 
which we were unable to locate a positive anti-RNP result in the medical record, it is 
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possible that anti-RNP was positive at one point in time but was not available in the 
medical record, either because of long duration of disease or related to accessing care 
in different locations over time.  The median duration of follow-up for prevalent cases 
was 10 years.  Second, MCTD does not have a specified ICD-9 code.  We drew from a 
set of codes likely to include all codes used for MCTD, but it is possible that we missed 
some cases that were coded differently.  For possible cases, detailed medical record 
abstraction was performed, reducing the risk of misclassification found in studies using 
administrative data only.  Third, we did not specifically exclude individuals who met 
classification criteria for SLE or other connective tissue diseases.  It is possible that we 
are overestimating the prevalence of MCTD by including patients with SLE or other 
connective tissue diseases.  However, due to the nature of connective tissue diseases 
and the limitations of classification criteria in clinical practice, and given that we 
excluded those with rheumatologist-diagnosed connective tissue diseases, we believe 
that our estimates are reasonable.  Fourth, for the cases diagnosed more recently, we 
were not able to follow them longitudinally to know if their diagnoses might evolve over 
time.  Fifth, the small number of cases limited the precision of our estimates.  This 
affected our ability to make comparisons to existing studies, precluded us from 
calculating incidence, and did not allow us to determine whether the lower prevalence 
by our primary definition in those 65 and older was due to chance or an effect of MCTD 
on longevity.  This limitation is inherent in studies of small populations, especially AI/AN 
populations.  Finally, although we used multiple definitions of MCTD, we only included 
one of the four criteria sets for MCTD in this study.  The strengths of this project include 
the opportunity to assess the prevalence of MCTD in a population-based registry in the 
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US and the ability to use several different case definitions to determine the range in 
prevalence and burden of disease. 
 
In summary, we found the prevalence of MCTD in the IHS Lupus Registry to be higher 
than described in the few previous studies of MCTD prevalence.  MCTD was more 
common in women, and was at least 7 times less common than SLE in this population.  
This study significantly adds to the limited literature on MCTD epidemiology.  
Epidemiologic studies of MCTD in other populations are warranted, and ideally would 
be able to add surveillance for differential outcomes to advance our knowledge of 
possible health disparities in MCTD prognosis in minority populations.  Finally, the high 
prevalence of SLE and MCTD in AI/AN populations suggests that studies investigating 
genetic and environmental factors in these populations could lead to insights into the 
pathogenesis of autoimmune diseases.   
  
13 
 
ACKNOWLEDGEMENTS: 
The authors would like to acknowledge the IHS Performance Evaluation System and 
the field abstractors (Amy Swango-Wilson, Alette Thompson, and Vivian Kelly) for their 
assistance with this registry.  We would also like to acknowledge colleagues from the 
Georgia Lupus Registry (GLR), Michigan Lupus Epidemiology and Surveillance (MILES) 
Program, California Lupus Surveillance Program (CLSP), and the Manhattan Lupus 
Surveillance Program (MLSP). 
  
14 
 
REFERENCES:  
1. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease--an 
apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable 
nuclear antigen (ENA). The American journal of medicine 1972;52:148-59. 
2. Cappelli S, Bellando Randone S, Martinovic D, et al. "To be or not to be," ten years after: 
evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 2012;41:589-98. 
3. Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheumatic 
diseases clinics of North America 2005;31:411-20, v. 
4. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC. Long-term outcome in 
mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 
1999;42:899-909. 
5. Ungprasert P, Crowson CS, Chowdhary VR, Ernste FC, Moder KG, Matteson EL. Epidemiology of 
Mixed Connective Tissue Disease 1985-2014: A Population Based Study. Arthritis Care Res (Hoboken) 
2016. 
6. Ortega-Hernandez OD, Shoenfeld Y. Mixed connective tissue disease: an overview of clinical 
manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol 2012;26:61-72. 
7. Alarcon-Segovia D, Villareal M. Classification and diagnostic criteria for mixed connective tissue 
disease. In: Kasukawa R, Sharp GC, eds. Mixed connective tissue disease and anti-nuclear antibodies. 
Amsterdam: Elsevier; 1987:33-40. 
8. Gunnarsson R, Molberg O, Gilboe IM, Gran JT, Group PS. The prevalence and incidence of mixed 
connective tissue disease: a national multicentre survey of Norwegian patients. Ann Rheum Dis 
2011;70:1047-51. 
9. Kaipiainen-Seppanen O, Aho K. Incidence of rare systemic rheumatic and connective tissue 
diseases in Finland. J Intern Med 1996;240:81-4. 
10. Maldonado ME, Perez M, Pignac-Kobinger J, et al. Clinical and immunologic manifestations of 
mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian 
population. J Rheumatol 2008;35:429-37. 
11. Tani C, Carli L, Vagnani S, et al. The diagnosis and classification of mixed connective tissue 
disease. Journal of autoimmunity 2014;48-49:46-9. 
12. Ferucci ED, Johnston JM, Gaddy JR, et al. Prevalence and incidence of systemic lupus 
erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009. 
Arthritis Rheumatol 2014;66:2494-502. 
13. Atkins C, Reuffel L, Roddy J, Platts M, Robinson H, Ward R. Rheumatic disease in the Nuu-Chah-
Nulth native Indians of the Pacific Northwest. J Rheumatol 1988;15:684-90. 
14. Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected U.S. population. Healthy 
People 2000 Stat Notes 2001:1-9. 
  
15 
 
Table 1: Unadjusted and age-adjusted prevalence of MCTD in AI/AN adults in 2007 
overall and by gender, by three case definitions  
 
Overall Female Male Female: 
Male 
Ratio 
Case Definition  
# of 
cases 
Unadjusted 
(95% CI) 
Age-
adjusted 
(95% 
CI) 
Unadjusted 
(95% CI) 
Unadjusted 
(95% CI) 
 
Primary: 
Rheumatologist 
diagnosis of 
MCTD AND 
Alarcón-
Segovia criteria 
documented 
8 
6.2  
(3.2-12.3) 
6.4  
(2.8-
12.8) 
10.7  
(5.4-21.2) 
0.0  
(0.0-7.2) 
Undefined 
(male = 0) 
Criteria:  
Alarcón-
Segovia criteria 
for MCTD 
documented in 
the medical 
record 
30 
23.4  
(16.4-33.4) 
26.3 
(17.4-
38.0) 
36.1  
(24.8-52.6) 
5.6 
(1.9-16.5) 
6.4 
Rheumatologist-
diagnosed: 
Rheumatologist 
diagnosis of 
MCTD alone 
23 
17.9  
(12.0-26.9) 
19.4  
(12.2-
29.3) 
29.4  
(19.4-44.6) 
1.9  
(0.3-10.6) 
15.7 
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Table 2:  
Individual criteria met 
Frequency of meeting individual Alarcón-Segovia criteria in the medical record (1 
serologic and 5 clinical), by three case definitions of MCTD.*   
Alarcón-Segovia 
criterion 
Primary 
Definition: 
Rheumatologist 
Diagnosis MCTD 
and Alarcón-
Segovia criteria 
documented 
n=8 
 
Criteria 
Definition: 
Alarcón-Segovia 
criteria 
documented 
n=30 
Rheumatologist
-Diagnosed 
Definition: 
Rheumatologist 
Diagnosis MCTD 
alone  
n=23 
 % % % 
Serologic: positive anti-
RNP antibody 100.0 100.0 60.9 
Clinical: 
1. Edema of the hands  62.5 70.0 26.1 
2. Synovitis 100.0 93.3 69.6 
3. Myositis 25.0 26.7 17.4 
4. Raynaud’s 
phenomenon 100.0 100.0 69.6 
5. Acrosclerosis 25.0 33.3 17.4 
All criteria fulfilled  100.0 100.0 34.8 
 
* No statistical comparisons between case definitions are provided because some 
patients are included in more than one group.  
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Figure 1 legend:  
Age specific rates (prevalence) per 100,000 population.  Prevalence per 100,000 
adult population in 2007 by age group for the primary definition, first alternate (criteria) 
definition, and second alternate (rheumatologist-diagnosed) definition. 
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Figure 1: 
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